BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced that it has filed an Investigational New Drug Applications (IND) with the U.S. FDA requesting permission to begin a Phase 1A human clinical trial for Thymosin beta 4 (Tß4) in healthy volunteers using an intravenous (IV) route of administration that will be tested in patients with ischemic cardiovascular disease in Phase 2. The company may initiate the study 30 days after filing an IND if it does not otherwise hear from the agency.
